Updated Retinal Bulletin

Advances in retinal research and cures.

CATT Trial

After a one year delay the CATT Trial will begin recruiting patients in January 2008. It will have two primary purposes:

  • Compare the safety and efficiency of Lucentis and Avastin
  • Determine whether or not as-needed dosing can produce a visual result that is as robust as what has previously been demonstrated with fixed dosing

The study chairman is David F. Martin, M. D., at Emory University.